Advanced nano-delivery systems in eradication: targeting, efficacy, and clinical translation.
Fuente:
PubMed
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Expert opinion on drug delivery
2026
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1868266144194887680 |
|---|---|
| author | Khan, Tehsin Ullah Sharaf, Mohamed Khan, Sohaib Ahmad, Khurshid Liu, Chen-Guang |
| author_facet | Khan, Tehsin Ullah Sharaf, Mohamed Khan, Sohaib Ahmad, Khurshid Liu, Chen-Guang Khan, Tehsin Ullah Sharaf, Mohamed Khan, Sohaib Ahmad, Khurshid Liu, Chen-Guang |
| collection | PubMed - marine biology |
| contents | Advanced nano-delivery systems in eradication: targeting, efficacy, and clinical translation. Khan, Tehsin Ullah Sharaf, Mohamed Khan, Sohaib Ahmad, Khurshid Liu, Chen-Guang Helicobacter pylori Helicobacter Infections Humans Anti-Bacterial Agents Drug Delivery Systems Animals Nanoparticle Drug Delivery System Drug Resistance, Bacterial Drug Design Nanoparticles Biological Availability Drug Carriers Gastric Mucosa infections demand innovative therapeutic strategies due to rising antibiotic resistance. This review consolidates recent advances in nanoparticle (NP)-based drug delivery systems engineered to optimize antimicrobial efficacy against . We critically examine the design, functionality, and performance of metallic, polymeric, lipid-based, and biomimetic nano-carriers, highlighting their advantages over conventional antibiotic delivery. Key innovations include: Lipid-based systems enabling synergistic co-delivery of hesperidin (0.064 μg mL⁻¹) and clarithromycin (0.15 mg mL⁻¹) for enhanced drug bioavailability; Polymeric NPs (e.g. rhamnolipid-chitosan hybrids) achieving deep biofilm penetration ( > 99% eradication) within gastric mucus at minimal inhibitory concentrations (32-132 µg/mL). These nanoplatforms demonstrate precision gastric-mucosa targeting, improved penetration of biological barriers, and controlled antimicrobial release. By maximizing localized drug delivery while minimizing systemic exposure, NP-based systems address critical limitations of current therapies, including resistance and microbiota disruption. We further emphasize the need for clinical validation to translate these delivery technologies into standardized treatments, ultimately reducing the global burden of -associated diseases. |
| format | Artículo científico |
| id | pubmed_41041824 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Expert opinion on drug delivery |
| record_format | pubmed |
| spellingShingle | Advanced nano-delivery systems in eradication: targeting, efficacy, and clinical translation. Khan, Tehsin Ullah Sharaf, Mohamed Khan, Sohaib Ahmad, Khurshid Liu, Chen-Guang Helicobacter pylori Helicobacter Infections Humans Anti-Bacterial Agents Drug Delivery Systems Animals Nanoparticle Drug Delivery System Drug Resistance, Bacterial Drug Design Nanoparticles Biological Availability Drug Carriers Gastric Mucosa Advanced nano-delivery systems in eradication: targeting, efficacy, and clinical translation. Khan, Tehsin Ullah Sharaf, Mohamed Khan, Sohaib Ahmad, Khurshid Liu, Chen-Guang Helicobacter pylori Helicobacter Infections Humans Anti-Bacterial Agents Drug Delivery Systems Animals Nanoparticle Drug Delivery System Drug Resistance, Bacterial Drug Design Nanoparticles Biological Availability Drug Carriers Gastric Mucosa infections demand innovative therapeutic strategies due to rising antibiotic resistance. This review consolidates recent advances in nanoparticle (NP)-based drug delivery systems engineered to optimize antimicrobial efficacy against . We critically examine the design, functionality, and performance of metallic, polymeric, lipid-based, and biomimetic nano-carriers, highlighting their advantages over conventional antibiotic delivery. Key innovations include: Lipid-based systems enabling synergistic co-delivery of hesperidin (0.064 μg mL⁻¹) and clarithromycin (0.15 mg mL⁻¹) for enhanced drug bioavailability; Polymeric NPs (e.g. rhamnolipid-chitosan hybrids) achieving deep biofilm penetration ( > 99% eradication) within gastric mucus at minimal inhibitory concentrations (32-132 µg/mL). These nanoplatforms demonstrate precision gastric-mucosa targeting, improved penetration of biological barriers, and controlled antimicrobial release. By maximizing localized drug delivery while minimizing systemic exposure, NP-based systems address critical limitations of current therapies, including resistance and microbiota disruption. We further emphasize the need for clinical validation to translate these delivery technologies into standardized treatments, ultimately reducing the global burden of -associated diseases. |
| title | Advanced nano-delivery systems in eradication: targeting, efficacy, and clinical translation. |
| topic | Helicobacter pylori Helicobacter Infections Humans Anti-Bacterial Agents Drug Delivery Systems Animals Nanoparticle Drug Delivery System Drug Resistance, Bacterial Drug Design Nanoparticles Biological Availability Drug Carriers Gastric Mucosa |
| url | https://pubmed.ncbi.nlm.nih.gov/41041824/ |